dr. Rosmince Beatrix Wattimury, SpPD-KHOM and Dr. dr. Shinta O. Wardhani, SpPD-KHOM (2024) “Perbandingan status koagulasi pasien Chronic Myeloid Leukemia antara Fase Kronis dan Fase Lanjutan yang mendapatkan Imatinib Mesilate”. Magister thesis, Universitas Brawijaya.
Abstract
LATAR BELAKANG: Chronic Myeloid Leukemia (CML)adalah kelainan mieloproliferatif yang ditandai dengan adanya kromosom Philadelphia. Imatinib Mesylate, inhibitor tirosin kinase, adalah pengobatan standar untuk CML. Abnormalitas koagulasi adalah komplikasi potensial pada pasien CML, namun perbedaan status koagulasi antara fase penyakit yang berbeda masih belum jelas. TUJUAN: Penelitian ini bertujuan untuk membandingkan status koagulasi antara pasien dalam fase kronis dan fase lanjutan CML yang menerima terapi Imatinib Mesylate. METODE: Studi potong lintang dilakukan dengan melibatkan pasien CML yang menjalani pengobatan dengan Imatinib Mesylate. Pasien dibagi menjadi dua kelompok berdasarkan fase penyakit: fase kronis dan fase lanjutan. Status koagulasi diukur menggunakan tromboelastografi dan diklasifikasikan menjadi hipokoagulabel, normokoagulabel, dan hiperkoagulabel. Data dianalisis menggunakan uji chi-square dengan nilai p < 0,05. HASIL: Penelitian ini melibatkan total 64 pasien, dengan 56 dalam fase kronis dan 8 dalam fase lanjutan. Sebagian besar status koagulasi pada kedua kelompok adalah normokoagulabel. Terdapat perbedaan dalam status koagulasi primer dan tersier (p=0,000; p=0,002). Nilai mean aplitudo, sudut alfa, dan LY30 lebih tinggi signifikan pada fase lanjutan dibandingkan fase kronis (p=0,005; p= 0,006; p=0,010) KESIMPULAN: Status koagulasi primer dan tersier pasien CML berbeda signifikan antara fase kronis dan fase lanjutan yang diukur dengan tromboelastografi.
English Abstract
BACKGROUND: Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome. Imatinib Mesylate, a tyrosine kinase inhibitor, is the standard treatment for CML. Coagulation abnormalities are potential complications in CML patients, but the differences in coagulation status between different disease phases remain unclear. OBJECTIVE: This study aims to compare the coagulation status between patients in the chronic phase and those in the advanced phase of CML who are receiving Imatinib Mesylate therapy. METHODS: A cross-sectional study was conducted involving CML patients undergoing treatment with Imatinib Mesylate. The patients were divided into two groups based on the disease phase: chronic phase and advanced phase (accelerated and blast crisis phases). Coagulation status was measured using thromboelastography and classified into hypocoagulable, normocoagulable, and hypercoagulable. Data analyzed using chi-square test with p-value < 0.05 RESULTS: The study included a total of 64 patients, with 56 in the chronic phase and 8 in the advanced phase. Most of the coagulaton statuses in both group were normocoaguable. There were differences in primary and tertiary coagulation statuses (p=0,000;p=0,002). The mean values of amplitude, alpha angle, and LY30 were significantly higher in the advanced phase compared to the chronic phase (p=0.005; p=0.006; p=0.010) CONCLUSION: The primary and tertiary coagulation status of CML patients differs significantly between the chronic phase and the advanced phase as measured by thromboelastograph
| Item Type: | Thesis (Magister) |
|---|---|
| Identification Number: | 0424060093 |
| Uncontrolled Keywords: | Leukemia Mieloid Kronis, Status Koagulasi, Tromboelastografi, Imatinib Mesylate |
| Divisions: | Profesi Kedokteran > Spesialis Ilmu Penyakit Dalam, Fakultas Kedokteran |
| Depositing User: | Unnamed user with username nova |
| Date Deposited: | 06 Sep 2024 05:13 |
| Last Modified: | 06 Sep 2024 05:13 |
| URI: | http://repository.ub.ac.id/id/eprint/229820 |
![[thumbnail of DALAM MASA EMBARGO]](http://repository.ub.ac.id/style/images/fileicons/text.png) |
Text (DALAM MASA EMBARGO)
Rosmince Beatrix Wattimury.pdf Restricted to Registered users only Download (4MB) |
Actions (login required)
 |
View Item |